Summary

Psoriatic Arthritis Treatment Market Summary

The global psoriatic arthritis market size was estimated at USD 11.35 billion in 2024 and is projected toprojected to reach USD 19.91 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The new product launches, promising pipeline, a significant rise in consumer awareness, and increasing disease burden are some factors expected to fuel market growth.

Psoriatic arthritis is a chronic degenerative condition associated with psoriasis. In the absence of proper and timely treatment, the disease may lead to irreversible joint damage. Although the exact causative factors remain unknown, research suggests that nearly 40% of cases are attributable to genetic factors.
Psoriatic arthritis may be misdiagnosed as rheumatoid arthritis or gout. However, heightened consumer awareness, aided by multiple campaigns organized by private and public organizations, is likely to reduce the rates of misdiagnosis or incorrect treatment. In addition, the high cost of treatment and the adverse effects of some drugs are expected to restrain market growth.

There is a significant paradigm shift in the treatment of psoriatic arthritis, driven by the targeted action of biologics and the emergence of biosimilars. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.
Healthcare infrastructure improvements and increased insurance coverage in emerging markets are also pivotal. Countries in Asia-Pacific and Latin America are witnessing rapid health system upgrades, enabling wider access to high-cost biologic therapies. As these markets mature, they present new opportunities for both multinational and domestic drug makers to tap into previously underserved populations.

Global Psoriatic Arthritis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psoriatic arthritis market report based on drug class, type, route of administration, and region:

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
• NSAIDs
• DMARD
• Biologics
• Others
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Prescriptions
• OTC
• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
• Topical
• Oral
• Injectable
• Regional Outlook (Revenue, USD Million, 2018 - 2026)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o Spain
o France
o Italy
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Type
1.2.3. Route of Administration
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class outlook
2.2.2. Type outlook
2.2.3. Route of Administration
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Psoriatic Arthritis Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Psoriatic Arthritis Treatment Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Psoriatic Arthritis Treatment Market: Drug Class Estimates & Trend Analysis
4.1. Drug Class Segment Dashboard
4.2. Psoriatic Arthritis Treatment Market: Drug Class Movement Analysis
4.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. NSAIDs
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. DMARDs
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Biologics
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Psoriatic Arthritis Treatment Market: Type Estimates & Trend Analysis
5.1. Type Segment Dashboard
5.2. Psoriatic Arthritis Treatment Market: Type Movement Analysis
5.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Prescriptions
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. OTC
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Psoriatic Arthritis Treatment Market: Route of Administration Estimates & Trend Analysis
6.1. Route of Administration Segment Dashboard
6.2. Psoriatic Arthritis Treatment Market: Route of Administration Movement Analysis
6.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Topical
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Oral
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Injectable
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Psoriatic Arthritis Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous bioprocessing market by Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Australia
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Argentina
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. UAE
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
8.4.1. AbbVie Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Amgen Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Johnson & Johnson Services, Inc.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Bristol-Myers Squibb Company
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Novartis AG
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Eli Lilly and Company
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Pfizer, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. UCB S.A.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives